Key Spec Table
|Species Reactivity||Key Applications||Host||Format||Antibody Type|
|H||WB, IHC, ELISA||M||Affinity Purified||Monoclonal Antibody|
|Presentation||Purified mouse monoclonal IgG1κ in buffer containing PBS without preservatives.|
|Safety Information according to GHS|
|Material Size||100 µg|
|Anti-Aggregated a-Synuclein, clone -VP1412161||VP1412161|
|Anti-Aggregated a-Synuclein, clone -VP15100026||VP15100026|
|Anti-Aggregated a-Synuclein, clone -VP1512070||VP1512070|
|Anti-Aggregated a-Synuclein, clone -VP1606270||VP1606270|
|Anti-Aggregated a-Synuclein, clone 5G4||VP1407100|
|Anti-Aggregated a-Synuclein, clone 5G4||VP1611151|
|Anti-Aggregated a-Synuclein, clone 5G4 - QVP1310071||QVP1310071|
|Anti-Aggregated a-Synuclein, clone 5G4 -QVP1508080||QVP1508080|
|Anti-Aggregated a-Synuclein, clone 5G4 -VP14010140||VP14010140|
|Anti-Aggregated a-Synuclein, clone 5G4 -VP1410140||VP1410140|
|Reference overview||Pub Med ID|
Unterberger, U; Lachmann, I; Voigtländer, T; Pirker, W; Berghoff, AS; Flach, K; Wagner, U; Geneste, A; Perret-Liaudet, A; Kovacs, GG
Clinical neuropathology 33 329-34 2014
With the aim to evaluate the significance and reliability of detecting disease-specific ?-synuclein in the cerebrospinal fluid (CSF) we developed an ELISA and bead-assay. We used a commercial antibody (5G4) that does not bind to the physiological monomeric form of ?-synuclein, but is highly specific for the disease-associated forms, including high molecular weight fraction of ?-sheet rich oligomers. We applied both tests in CSF from a series of neuropathologically confirmed ?-synucleinopathy cases, including Parkinson' disease dementia (PDD) and dementia with Lewy bodies (DLB) (n = 7), as well as Alzheimer' disease (n = 6), and control patients without neurodegenerative pathologies (n = 9). Disease-specific ?-synuclein was detectable in the CSF in a subset of patients with ?-synuclein pathology in the brain. When combined with the analysis of total ?-synuclein, the bead-assay for disease-specific ?-synuclein was highly specific for PDD/DLB. Detection of disease-associated ?synuclein combined with the total levels of ?-synuclein is a promising tool for the in-vivo diagnosis of ?-synucleinopathies, including PDD and LBD.
|Intracellular processing of disease-associated ?-synuclein in the human brain suggests prion-like cell-to-cell spread.|
Kovacs, GG; Breydo, L; Green, R; Kis, V; Puska, G; L?rincz, P; Perju-Dumbrava, L; Giera, R; Pirker, W; Lutz, M; Lachmann, I; Budka, H; Uversky, VN; Molnár, K; László, L
Neurobiology of disease 69 76-92 2014
Dementia with Lewy bodies (DLB), Parkinson's disease (PD) and multiple system atrophy are characterized by the deposition of disease-associated ?-synuclein. In the present study we 1) examined the molecular specificity of the novel anti-?-synuclein 5G4 antibody; 2) evaluated immunoreactivity patterns and their correlation in human brain tissue with micro- and astrogliosis in 57 cases with PD or DLB; and 3) performed a systematic immunoelectron microscopical mapping of subcellular localizations. 5G4 strongly binds to the high molecular weight fraction of ?-sheet rich oligomers, while no binding to primarily disordered oligomers or monomers was observed. We show novel localizations of disease-associated ?-synuclein including perivascular macrophages, ependyma and cranial nerves. ?-Synuclein immunoreactive neuropil dots and thin threads associate more with glial reaction than Lewy bodies alone. Astrocytic ?-synuclein is an important component of the pathology. Furthermore, we document ultrastructurally the pathway of processing of disease-associated ?-synuclein within neurons and astroglial cells. Interaction of mitochondria and disease-associated ?-synuclein plays a key role in the molecular-structural cytopathogenesis of disorders with Lewy bodies. We conclude that 1) the 5G4 antibody has strong selectivity for ?-sheet rich ?-synuclein oligomers; 2) Lewy bodies themselves are not the most relevant morphological substrate that evokes tissue lesioning; 3) both neurons and astrocytes internalize disease-associated ?-synuclein in the human brain, suggesting prion-like cell-to-cell spread of ?-synuclein by uptake from surrounding structures, as shown previously in experimental observations.
|In vivo markers of Parkinson's disease and dementia with Lewy bodies: current value of the 5G4 ?-synuclein antibody.|
Maetzler, W; Pilotto, A; Apel, A; Deuschle, C; Kuebart, G; Heinzel, S; Liepelt-Scarfone, I; Schulte, C; Reusch, D; Schleicher, E; Rothfuss, O; Schneider, A; Dodel, R; Gasser, T; Berg, D
Acta neuropathologica 128 893-5 2014
|An antibody with high reactivity for disease-associated ?-synuclein reveals extensive brain pathology.|
Kovacs, Gabor G, et al.
Acta Neuropathol., 124: 37-50 (2012) 2012
?-Synuclein is the major protein associated with Lewy body dementia, Parkinson's disease and multiple system atrophy. Since ?-synuclein is present in the brain in physiological conditions as a presynaptic protein, it is crucial to characterize disease-associated modifications to develop an in vivo biomarker. With the aim to develop antibodies showing high specificity and sensitivity for disease-associated ?-synuclein, synthetic peptides containing different amino acid sequences were used for immunization of mice. After generation of ?-synuclein aggregates, ELISA and immunoblotting were used to test the specificity of antibodies. Tissue microarray sections originating from different human ?-synucleinopathies were used to compare immunostaining with other, commercially available antibodies. Immunization of mice with the peptide TKEGVVHGVATVAE (amino acid 44-57 of ?-synuclein) resulted in the generation of a monoclonal antibody (5G4), which was able to bind aggregated ?-synuclein preparation in sandwich ELISA or coated on magnetic beads. 5G4 proved to be superior to other antibodies in comparative immunohistochemical studies by revealing more widespread and distinct ?-synuclein pathology. Immunoblotting of human brain tissue revealed an additional band seen in dementia with Lewy bodies, whereas the band representing monomeric ?-synuclein was very weak or lacking. In summary, the 5G4 antibody is most promising for re-evaluation of archival material and may offer new perspective for the development of in vivo diagnostic assays for detecting disease-associated ?-synuclein in body fluids.